Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
Saved in:
| Title: | Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer. |
|---|---|
| Authors: | Miwa K; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan., Kawasaki R; Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan., Shimokawa M; Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan., Otsuka T; Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan., Tanaka T; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan., Fukahori M; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan., Shibuki T; Department for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan., Nakazawa J; Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan., Arima S; Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan., Koga F; Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan., Ueda Y; Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan., Kubotsu Y; Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan., Shimokawa H; Department of Hematology Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.; Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan., Takeshita S; Department of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan., Nishikawa K; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan., Komori A; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan., Otsu S; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan., Hosokawa A; Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan., Sakai T; Department of Medical Oncology, NHO Kumamoto Medical Center, Kumamoto, Japan., Oda H; Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan., Kawahira M; Department of Gastroenterology, Kagoshima Kouseiren Hospital, Kagoshima, Japan., Arita S; Department of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan., Honda T; Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Taguchi H; Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.; Department of Gastroenterology, Kagoshima City Hospital, Kagoshima, Japan., Tsuneyoshi K; Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan., Fujita T; Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan., Sakae T; Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan., Kawaguchi Y; Department of Gastroenterology, Asakura Medical Association Hospital, Fukuoka, Japan., Shirakawa T; Clinical Hematology Oncology Treatment Study Group, Fukuoka, Japan.; Department of Medical Checkup Center, Eikoh Hospital, Fukuoka, Japan., Mizuta T; Department of Internal Medicine, Fujikawa Hospital, Saga, Japan., Mitsugi K; Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Jul 17; Vol. 15, pp. 1626689. Date of Electronic Publication: 2025 Jul 17 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1626689 |
